Sydney’s COVID northern seashores cluster grows by seven, Better Sydney restrictions determination to return, new UK COVID pressure in NSW


Drug makers together with BioNTech and Moderna are scrambling to check their COVID-19 vaccines in opposition to the new fast-spreading variant of the virus that’s raging in Britain, the newest problem within the breakneck race to curb the pandemic.

However there may be some promising information: Ugur Sahin, chief govt of Germany’s BioNTech, stated in a single day it was “extremely possible” that its vaccine developed in partnership with Pfizer will present an immune response in opposition to the brand new variant.

BioNTech said it was highly likely its vaccine, developed with partner Pfizer, would provide protection against the new virus strain.

BioNTech stated it was extremely possible its vaccine, developed with associate Pfizer, would supply safety in opposition to the brand new virus pressure.Credit score:AP

“The vaccine accommodates greater than 1270 amino acids, and solely 9 of them are modified (within the mutant virus). That signifies that 99 per cent of the protein remains to be the identical,” he stated.

Exams are ongoing and, even when Sahin’s principle proves incorrect, he stated scientists might engineer a vaccine which fully mimics the brand new mutation inside six weeks.

You can read the full story here.